Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis
Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) responses of FMXIN002, an intranasal epinephrine powder, compared with the EpiPen intramuscular autoinjector, after single and double doses, in healthy adults with a history of allergic rhinitis.